A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2019-05-24
Target enrollment:
Participant gender:
Summary
This study is evaluating the safety, tolerability, and feasibility of GRF6019, a
plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild
to moderate Alzheimer's disease.